Impact of Positive CD4 Cells on Event-free Survival in Follicular Lymphoma Patients

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Sep 9

PMID 39248131

Authors

Cong Li

Na Guo

Shuiyun Han

Haifeng Yu

Tao Lei

Xi Chen

Shuailing Peng

Haiyan Yang

Meijuan Wu

Affiliations

Soon will be listed here.

Abstract

Objective: Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial.

Methods: Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1-3A. Early failure was described as failing to achieve event-free survival (EFS) at 12 or 24 months.

Results: There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with <20% of positive CD4 cells, patients with ≥20% of positive CD4 cells exhibited a significant lower risk of early failure (2-year EFS rate: 56.7% vs 73.5%, p = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (p = 0.002) and median OS (p = 0.007) were significantly different.

Conclusions: This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.

Citing Articles

Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.

Enemark M, Hemmingsen J, Jensen M, Kridel R, Ludvigsen M Int J Mol Sci. 2024; 25(20).

PMID: 39456961 PMC: 11508793. DOI: 10.3390/ijms252011179.

References

Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P . Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3):1110-7. DOI: 10.1200/JCO.1997.15.3.1110. View

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger A, Szczepanowski M . Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9):1111-1122. DOI: 10.1016/S1470-2045(15)00169-2. View

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View

Glas A, Knoops L, Delahaye L, Kersten M, Kibbelaar R, Wessels L . Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007; 25(4):390-8. DOI: 10.1200/JCO.2006.06.1648. View

Al-Tourah A, Gill K, Chhanabhai M, Hoskins P, Klasa R, Savage K . Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26(32):5165-9. DOI: 10.1200/JCO.2008.16.0283. View

Ardeshna K, Qian W, Smith P, Braganca N, Lowry L, Patrick P . Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014; 15(4):424-35. DOI: 10.1016/S1470-2045(14)70027-0. View

Ame-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R . Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia. 2011; 26(5):1053-63. PMC: 3428269. DOI: 10.1038/leu.2011.301. View

Araujo-Ayala F, Perez-Galan P, Campo E . Vulnerabilities in the tumor and microenvironment in follicular lymphoma. Hematol Oncol. 2021; 39 Suppl 1:83-87. DOI: 10.1002/hon.2855. View

10.

Zelenetz A, Gordon L, Abramson J, Advani R, Bartlett N, Caimi P . NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019; 17(6):650-661. DOI: 10.6004/jnccn.2019.0029. View

11.

Kiaii S, Clear A, Ramsay A, Davies D, Sangaralingam A, Lee A . Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol. 2013; 31(21):2654-61. PMC: 3709054. DOI: 10.1200/JCO.2012.44.2137. View

12.

Bachy E, Maurer M, Habermann T, Gelas-Dore B, Maucort-Boulch D, Estell J . A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018; 132(1):49-58. PMC: 6034646. DOI: 10.1182/blood-2017-11-816405. View

13.

Casulo C, Byrtek M, Dawson K, Zhou X, Farber C, Flowers C . Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. PMC: 4879714. DOI: 10.1200/JCO.2014.59.7534. View

14.

Wahlin B, Aggarwal M, Montes-Moreno S, Gonzalez L, Roncador G, Sanchez-Verde L . A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010; 16(2):637-50. DOI: 10.1158/1078-0432.CCR-09-2487. View

15.

Yuda S, Maeshima A, Taniguchi H, Ito Y, Hatta S, Suzuki T . Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma. Eur J Haematol. 2021; 107(1):157-165. DOI: 10.1111/ejh.13637. View

16.

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-62. DOI: 10.1200/JCO.2008.21.3991. View

17.

Horning S, Rosenberg S . The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984; 311(23):1471-5. DOI: 10.1056/NEJM198412063112303. View

18.

Laurent C, Dietrich S, Tarte K . Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2023; 143(12):1080-1090. DOI: 10.1182/blood.2023021000. View

19.

Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

20.

Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N . Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol. 2020; 22(7):896-906. DOI: 10.1038/s41556-020-0532-x. View